drugset / Trial / NCT00375427
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to assess the clinical benefit of two different dosing schedules of zoledronic acid in patients with metastatic bone lesions from breast cancer who have already been treated with zoledronic acid for about one year.
Timeline
- Start
- 2006-02
- Primary completion
- 2010-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | 3 mg | Intravenous |
| Subject | Zoledronic acid | Other / unclassified | 3.3 mg | Intravenous |
| Subject | Zoledronic acid | Other / unclassified | 3.5 mg | Intravenous |
| Subject | Zoledronic acid | Other / unclassified | 4 mg | Intravenous |